中药复方联合三七粉辨证治疗慢性萎缩性胃炎伴糜烂的多中心随机对照试验
本研究为多中心、随机、阳性药物对照临床试验,纳入216例慢性萎缩性胃炎伴糜烂患者,随机分为铝镁加混悬液对照组、中药复方联合三七粉组(试验组1)及中药复方联合三七粉与浙贝母粉组(试验组2),治疗4周。结果显示,中药治疗在改善胃黏膜糜烂和病理评分方面与抗酸剂疗效相当,但在改善 dysplasia(异型增生)和临床症状方面优于抗酸剂,且安全性良好。
要点
- 中药复方联合三七粉辨证治疗可改善胃黏膜糜烂,疗效与铝镁加混悬液相当。
- 中药治疗在改善异型增生方面优于抗酸剂,且能显著改善临床症状。
- 中药治疗组与对照组不良事件发生率无显著差异,无严重不良事件。
核心结论
- 中药复方联合三七粉辨证治疗慢性萎缩性胃炎伴糜烂在改善胃黏膜糜烂和病理评分方面与铝镁加混悬液疗效相当。
- 中药治疗在改善异型增生和临床症状方面优于铝镁加混悬液,整体临床结局更优。
研究设计与样本
- 多中心、随机、阳性药物对照临床试验,纳入216例慢性萎缩性胃炎伴糜烂患者。
- 患者随机分为三组:对照组(铝镁加混悬液)、试验组1(中药复方+三七粉)、试验组2(中药复方+三七粉+浙贝母粉),治疗4周。
主要发现
- 治疗后各组胃黏膜糜烂均显著改善(P<0.05),但组间糜烂评分及疗效率无显著差异(P>0.05)。
- 对照组急性炎症、慢性炎症、萎缩和肠化生总分显著降低(P<0.05),但异型增生无显著改善(P>0.05)。
- 试验组1慢性炎症、萎缩、肠化生和异型增生评分显著降低(P<0.05),但急性炎症无改善(P>0.05)。
- 试验组2仅萎缩评分显著降低(P<0.05),其他病理评分无显著改善(P>0.05)。
- 试验组主要症状评分和总症状评分低于对照组(P<0.05),消化不良、排便和PRO总分组间比较有统计学差异(P<0.05)。
关键数值与推荐
- 对照组胃黏膜糜烂疗效率为69.12%,试验组1为73.24%,试验组2为69.01%,组间无统计学差异(P>0.05)。
- 不良事件发生率:试验组1为4.23%(3例),对照组为4.41%(3例);不良反应发生率:试验组1为4.23%(3例),对照组为2.94%(2例),组间无显著差异(AE P=0.2213,ADR P=0.2872)。
临床怎么用
- 对于慢性萎缩性胃炎伴糜烂患者,可考虑在辨证基础上使用中药复方联合三七粉,以改善胃黏膜糜烂和病理评分。
- 中药治疗在改善异型增生和临床症状方面可能优于抗酸剂,可作为临床选择之一。
局限性
- 研究周期较短(4周),长期疗效未评估。
- 样本量有限,最终分析纳入202例患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In this study, Chinese herbal compound prescriptions combined with Chinese medicine powder were evaluated for the treatment of chronic atrophic gastritis with erosion. METHODS: This multi-center, randomized, positive drug control clinical trial randomly assigned 216 patients with chronic atrophic gastritis with erosion to three groups: (1) control group: aluminum plus magnesium suspension thrice per day for 4 weeks; (2) test group 1: Chinese herbal compound prescriptions twice a day plus Sanqi (Panax notoginseng) powder twice a day for 4 weeks; (3) test group 2: Chinese herbal compound prescriptions twice a day plus Sanqi (Panax notoginseng) powder and Zhebeimu (Fritillaria thunbergii Miq.) powder twice a day for 4 weeks. The primary endpoint (improvement of gastric mucosal erosion; improvement of gastric mucosal pathology) and secondary endpoints (improvement of clinical symptoms scores; improvement of the patient-reported outcome [PRO] instrument for chronic gastrointestinal diseases) were assessed using endoscopy at week 4 following the treatment. Drug-related adverse events (AEs) and adverse drug reactions (ADRs) were also compared. RESULTS: The final analysis included 202 patients (control group, 63; test group 1, 69; test group 2, 70). At week 4, using within-group comparison, gastric mucosal erosion improved in each group following treatment with a significant difference (P < 0.05); there were no statistically significant differences in gastric mucosal erosion scores among the groups after treatment (P > 0.05); in terms of improvement of gastric mucosal erosion, the efficacy rate of the control group was 69.12%, the efficacy rate of the test group 1 was 73.24%, and the efficacy rate of the test group 2 was 69.01% and efficacy rate among the groups was not statistically significant (P > 0.05). As determined by acute inflammation, chronic inflammation, atrophy, intestinal metaplasia, and dysplasia, the pathological score (total score and the highest score) did not differ statistically among groups following treatment (P > 0.05); within the control group, the total scores of acute inflammation, chronic inflammation, atrophy, and intestinal metaplasia were significantly decreased (P < 0.05), but there was no significant improvement in dysplasia (P > 0.05); in the test group 1, chronic inflammation, atrophy, and intestinal metaplasia and dysplasia scores were significantly decreased (P < 0.05), but acute inflammation did not improve (P > 0.05); there was a significant reduction in the atrophy score in test group 2 (P < 0.05), but no improvement in the scores of acute inflammation, chronic inflammation, intestinal metaplasia, and dysplasia was observed (P > 0.05). Similarly, within the control group, the highest scores of acute inflammation, chronic inflammation, atrophy, and intestinal metaplasia were significantly decreased (P < 0.05), but there was no significant improvement in dysplasia (P > 0.05); there was a significant reduction in highest scores of atrophy, intestinal metaplasia, and dysplasia (P < 0.05) in test group 1, but the highest scores didn't not improve with acute inflammation and chronic inflammation (P > 0.05); there was a significant reduction in the highest atrophy score in test group 2 (P < 0.05), but no improvement in the highest scores of acute inflammation, chronic inflammation, intestinal metaplasia, and dysplasia was observed (P > 0.05). Compared to the control group, the main symptom scores and total symptom scores in the test groups were lower following treatment, with a statistically significant difference (P < 0.05); the analysis of covariance with center, erosion type, and group as factors was applied, and the comparison among the groups in dyspepsia, defecation, and total PRO instrument scores were statistically significant (P < 0.05). In the study period, AEs were reported in 3 (4.23%) patients in the test group 1 and 3 (4.41%) patients in the control group; ADRs were confirmed in 3 (4.23%) patients from the test group 1 and 2 (2.94%) from the control group. AEs and ADRs were not statistically significantly different among groups (AE, P = 0.2213; ADR, P = 0.2872). No serious AE or ADR was reported. CONCLUSIONS: This study has shown that both aluminum plus magnesium suspension and Chinese herbal compound prescriptions together with Panax notoginseng powder are capable of improving gastric mucosal erosion and reducing gastric mucosal pathological scores, and there were no statistically significant differences among the groups in primary endpoints, indicating that Chinese herbal therapy can achieve similar efficacy than antacids in terms of primary outcomes. The aluminum plus magnesium suspension is comparable to Chinese herbal therapy in improving atrophy and intestinal metaplasia, and is inferior to Chinese herbal therapy in improving dysplasia. In addition, the Chinese herbal therapy significantly outperforms the aluminum plus magnesium suspension in improving symptoms. Therefore, the overall clinical outcome of Chinese herbal compound prescriptions together with Panax notoginseng powder based on TCM syndrome patterns in the treatment of erosive gastritis is superior to that of antacids. Trial registration ChiCTR, ChiCTR-IPR-15005905. Registered 22 January 2015, https://www.chictr.org.cn/showproj.aspx?proj=10359.
引用
- Zhang T, Zhang B, Xu J, et al. Chinese herbal compound prescriptions combined with Chinese medicine powder based on traditional Chinese medicine syndrome differentiation for treatment of chronic atrophic gastritis with erosion: a multi-center, randomized, positive-controlled clinical trial. Chin Med. 2022. PMID: 36550503. doi:10.1186/s13020-022-00692-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。